

Disclaimer: This document is an English translation of the original document in Japanese and has been prepared solely for reference purposes. In the event of any discrepancy between this English translation and the original in Japanese, the original shall prevail in all respects.



June 1, 2023

To whom it may concern:

|                |                                                                                                                                              |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Company name   | KISSEI PHARMACEUTICAL CO., LTD.                                                                                                              |
| Representative | Mutsuo Kanzawa, Chairman and CEO<br>(Stock code 4547; Prime Market, Tokyo Stock Exchange)                                                    |
| Contact        | Takahide Kitahara, Managing Director,<br>Department Manager of Corporate Finance<br>and Management Department<br>(Telephone +81-263-25-9081) |

### Notice Concerning Status of Acquisition of the Company's Own Shares

(Acquisition of Company's own shares pursuant to the provisions of the Articles of Incorporation based on the provisions of Article 165, Item 2 of the Corporate Law)

KISSEI PHARMACEUTICAL CO., LTD. (the "Company") announces status of acquisition of its own shares pursuant to Article 156 of the Corporate Law after applying the provisions of Article 165, Item 3 of the Law, which was announced on May 8, 2023, as follows.

1. Type of shares acquired: Common shares of the Company
2. Total number of shares acquired: 88,700 shares
3. Total amount of shares acquired: 253,783,500 yen
4. Period of acquisition: Started on May 10, 2023 and ended on May 31, 2023 (based on contract date)
5. Acquisition method: Market purchases on the Tokyo Stock Exchange based on a discretionary trading contract regarding acquisition of own shares

(Reference)

1. Details of the resolution at the meeting of Board of Directors held on May 8, 2023
  - 1) Type of shares to be acquired: Common shares of the Company
  - 2) Total number of shares to be acquired: Up to 2,000,000 shares  
(Percentage of total number of issued shares (excluding treasury shares) :4.34%)
  - 3) Total acquisition cost: 6 billion yen (maximum)
  - 4) Acquisition period: From May 10, 2023 to March 29, 2024
  - 5) Acquisition method: Market purchases on the Tokyo Stock Exchange
    1. Purchases through the Tokyo Stock Exchange Trading Network Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)
    2. Market purchases based on a discretionary trading contract regarding acquisition of own shares
2. Cumulative number and value of own shares acquired so far based on the above resolution at the Board of Directors meeting (As of May 31, 2023)
  - 1) Total number of shares acquired: 88,700 shares
  - 2) Total amount of shares acquired: 253,783,500 yen